APA (7th ed.) Citation

Fauvre, A., Ursino, C., Garambois, V., Culerier, E., Milazzo, L., Vezzio-Vié, N., . . . Faget, J. (2025). Oxaliplatin, ATR inhibitor and anti-PD-1 antibody combination therapy controls colon carcinoma growth, induces local and systemic changes in the immune compartment, and protects against tumor rechallenge in mice. Journal for immunotherapy of cancer, 13(3), e010791. https://doi.org/10.1136/jitc-2024-010791

Chicago Style (17th ed.) Citation

Fauvre, Alexandra, et al. "Oxaliplatin, ATR Inhibitor and Anti-PD-1 Antibody Combination Therapy Controls Colon Carcinoma Growth, Induces Local and Systemic Changes in the Immune Compartment, and Protects Against Tumor Rechallenge in Mice." Journal for Immunotherapy of Cancer 13, no. 3 (2025): e010791. https://doi.org/10.1136/jitc-2024-010791.

MLA (9th ed.) Citation

Fauvre, Alexandra, et al. "Oxaliplatin, ATR Inhibitor and Anti-PD-1 Antibody Combination Therapy Controls Colon Carcinoma Growth, Induces Local and Systemic Changes in the Immune Compartment, and Protects Against Tumor Rechallenge in Mice." Journal for Immunotherapy of Cancer, vol. 13, no. 3, 2025, p. e010791, https://doi.org/10.1136/jitc-2024-010791.